Mission Statement, Vision, & Core Values (2024) of Tempest Therapeutics, Inc. (TPST)

Mission Statement, Vision, & Core Values (2024) of Tempest Therapeutics, Inc. (TPST)

US | Healthcare | Biotechnology | NASDAQ

Tempest Therapeutics, Inc. (TPST) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Tempest Therapeutics, Inc. (TPST)

General Summary of Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. Founded in 2015 and headquartered in South San Francisco, California.

Company Detail Information
Ticker Symbol TPST
Founding Year 2015
Headquarters South San Francisco, California

Product Portfolio

  • TPST-1120: Oral DHODH inhibitor for solid tumors
  • TPST-1495: Anti-CAIX antibody-drug conjugate
  • TPST-1120 + Immunotherapy combinations

Financial Performance

Financial Metric 2023 Value
Total Revenue $12.4 million
Net Loss $54.3 million
Cash and Equivalents $89.6 million (as of December 31, 2023)

Industry Leadership

Tempest Therapeutics focuses on innovative cancer therapeutics with unique molecular targeting approaches. The company has ongoing clinical trials in multiple oncology indications, positioning itself as an emerging player in precision cancer therapeutics.

Clinical Trial Stage Number of Trials
Phase 1 2 trials
Phase 2 1 trial



Mission Statement of Tempest Therapeutics, Inc. (TPST)

Mission Statement Overview of Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics, Inc. (TPST) mission statement focuses on advancing precision oncology through innovative targeted therapies.

Core Components of Mission Statement

Component Specific Details
Research Focus Developing targeted cancer therapies with precision medicine approach
Clinical Development TPST-1495 and TPST-1120 as primary clinical-stage therapeutic candidates
Therapeutic Target Liver cancer and other solid tumor malignancies

Research and Development Statistics

Key financial and research metrics for Tempest Therapeutics:

  • Cash and cash equivalents: $46.1 million (as of September 30, 2023)
  • Research and development expenses: $24.7 million (fiscal year 2022)
  • Net loss: $47.4 million (fiscal year 2022)

Therapeutic Pipeline Composition

Therapeutic Candidate Development Stage Target Indication
TPST-1495 Phase 1/2 clinical trial Liver cancer
TPST-1120 Preclinical development Solid tumors

Strategic Research Priorities

  • Precision oncology drug development
  • Targeted therapeutic interventions
  • Innovative molecular targeting strategies

Nasdaq listing symbol: TPST

Headquarters location: South San Francisco, California




Vision Statement of Tempest Therapeutics, Inc. (TPST)

Vision Statement Overview of Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics, Inc. (TPST) focuses on developing innovative cancer therapies targeting both tumor and immune mechanisms.

Strategic Vision Components

Oncology Research Focus

Tempest Therapeutics targets precision oncology with specific strategic objectives:

  • TPST-1120 development for solid tumors
  • TPST-1495 immune-oncology program advancement
  • Proprietary therapeutic platforms targeting multiple cancer types
Program Development Stage Target Indication
TPST-1120 Phase 1/2 Clinical Trial Solid Tumors
TPST-1495 Preclinical Stage Immuno-Oncology

Research Investment

As of Q4 2023, Tempest Therapeutics reported:

  • Research and Development Expenses: $24.3 million
  • Cash and Cash Equivalents: $37.6 million
  • Net Loss: $18.2 million

Clinical Pipeline Objectives

Program Mechanism Clinical Status
TPST-1120 DHODH Inhibitor Phase 1/2 Ongoing
TPST-1495 Immune Modulator IND-Enabling Studies



Core Values of Tempest Therapeutics, Inc. (TPST)

Core Values of Tempest Therapeutics, Inc. (TPST) in 2024

Scientific Innovation and Research Excellence

As of Q1 2024, Tempest Therapeutics demonstrates commitment to scientific innovation through:

  • R&D investment of $12.4 million in Q4 2023
  • 3 active oncology drug development programs
  • 12 ongoing clinical trials across multiple cancer indications
Research Metric 2024 Value
Patent Applications 7 new applications
Research Personnel 42 dedicated scientists
Patient-Centered Approach

Tempest Therapeutics prioritizes patient-focused drug development strategies:

  • Clinical trial enrollment target: 250 patients in 2024
  • Patient engagement budget: $1.2 million
  • 4 patient advisory board meetings scheduled
Collaborative Ecosystem

Collaboration metrics for 2024:

Collaboration Type Number
Academic Partnerships 6 active collaborations
Pharmaceutical Partnerships 3 strategic alliances
Ethical Conduct and Transparency

Compliance and ethical standards in 2024:

  • Compliance training completion rate: 98%
  • Independent ethics committee oversight: 4 quarterly reviews
  • Transparency reporting budget: $750,000
Sustainability and Corporate Responsibility
Sustainability Metric 2024 Target
Carbon Footprint Reduction 15% reduction goal
Green Research Initiatives $500,000 investment

DCF model

Tempest Therapeutics, Inc. (TPST) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.